Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
Bio-Techne TECH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks Consensus Estimate by 10.5%. The bottom line improved from the year-ago figure of 40 cents.
Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript
Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will be open for questions following management's prepared remarks. During our Q&A session, please limit yourself to one question and one follow-up.
Bio-Techne beats Q2 earnings estimates on improving demand for biotech products
Bio-Techne beat second-quarter profit and revenue estimates on Wednesday, helped by growth in its protein sciences unit that makes products to develop therapies
Bio-Techne Corp. Q2 Profit Increases, Beats Estimates
Bio-Techne Corp. (TECH) announced earnings for its second quarter that increased from last year and beat the Street estimates. The
Bio-Techne Fiscal Q2 Revenues up 9 Percent
The firm's Protein Sciences segment saw revenues increase 7 percent, while the Diagnostics and Spatial Biology segment's revenues rose 12 percent.
Techne (TECH) Tops Q2 Earnings and Revenue Estimates
Techne (TECH) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.40 per share a year ago. These figures are adjusted for non-recurring items.
Bio-Techne signals high single-digit growth recovery by Q4 2025, driven by biopharma momentum
Q2 2025 Management View CEO Kim Kelderman highlighted 9% organic revenue growth for the quarter, driven by strong performance in biopharma end markets, particularly large pharma, which benefited GMP ...
Bio-Techne (NASDAQ:TECH) Surprises With Strong Q4, Stock Soars
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2024 results topping the market’s revenue expectations, with ...
Bio-Techne reports Q2 adjusted EPS 42c, consensus 38c
Reports Q2 revenue $297.03M, consensus $285.42M. “The Bio-Techne (TECH) team once again executed at a high level and delivered strong second ...
Bio-Techne Corporation: Bio-Techne Releases Second Quarter Fiscal 2025 Results
Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, ...
Bio-Techne Declares Dividend
Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be ...
Bio-Techne Corp. stock underperforms Thursday when compared to competitors
This was the stock's second consecutive day of losses.
Bio-Techne adds Dr. Amy E. Herr to its Board of Directors
Corporation (NASDAQ: TECH), a global life sciences company valued at $11.45 billion, has announced the appointment of Dr. Amy E. Herr as an independent director on its Board of Directors. Dr. Herr ...